Completed PHASE2 NCT00013585

Safety and Effectiveness of the Selegiline Patch for Decreased Mental Function in HIV Patients

Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Cognition Disorders HIV Infections

Interventions Selegiline hydrochloride

Updated 7 times since 2017 Last updated: Oct 28, 2021 Completion: Dec 31, 2005

A PHASE2 clinical study on Cognition Disorders and HIV Infections, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Neurological Disorders and Stroke (NINDS)
Neurologic AIDS Research Consortium (NARC)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Chapel Hill, United States , Chicago, United States , Honolulu, United States , Los Angeles, United States , New York, United States , Philadelphia, United States , Providence, United States , Rochester, United States and 3 more locations